Patents Assigned to Charite Universitatsmedizin
-
Publication number: 20200018748Abstract: The invention provides a method of assigning to a patient a likelihood of having a kidney disease, or a likelihood of undergoing kidney transplant rejection, comprising the steps of providing a urine sample from the patient and determining the concentration of T cells, podocytes and proximal tubular epithelial cells. The ratios of these cell types are used for determining the risk of a kidney disease or transplant rejection.Type: ApplicationFiled: March 23, 2018Publication date: January 16, 2020Applicant: CHARITÉ-UNIVERSITÄTSMEDIZIN BERLINInventors: Philipp ENGHARD, Nina GÖRLICH, Hannah Antonia BRAND, Valerie LANGHANS, Petra REINKE
-
Publication number: 20200010520Abstract: The invention relates to the use of a uromodulin polypeptide in prevention or therapy of vascular calcification or a disease caused by, or related to, vascular calcification, particularly vascular calcification in chronic kidney disease, in diabetes, in aging and in atherosclerosis.Type: ApplicationFiled: February 27, 2018Publication date: January 9, 2020Applicant: Charité Universitätsmedizin BerlinInventors: Jakob VÖLKL, Ioana ALESUTAN, Jürgen SCHERBERICH
-
Patent number: 10508302Abstract: The invention relates to a control preparation (e.g. comprising microorganism control cells embedded in a cold polymerising resin or plastic) for use in a method for detection of a target microorganism in microbiological pathology, comprising a plurality of section bodies joint by a joining polymer, wherein each section body comprises a matrix polymer (e.g. a cold polymerising resin or plastic). A first section body comprises a nucleic acid sequence specific for the target microorganism (e.g. microorganism cells used as positive control). A second section body comprises a second nucleic acid sequence, which in comparison to said first nucleic acid sequence, contains a deletion, an additional nucleoside or a different nucleoside in one, two, three or four positions of said second nucleic acid sequence and which does not hybridize to said first nucleic acid sequence under stringent conditions (e.g.Type: GrantFiled: January 27, 2016Date of Patent: December 17, 2019Assignee: CHARITE UNIVERSITATSMEDIZIN BERLINInventor: Annette Moter
-
Patent number: 10495646Abstract: The invention provides the art with a powerful diagnostic method of distinguishing relapse-remitting MS subjects from progressive MS subjects, based on the measurement of serum concentrations of N-acetylglucosamine (GlcNAc,), for the first time enabling rapid diagnosis of the progressive form of MS. GlcNAc serum concentration can also be used to assess neurodegenerative status and MS progression in subjects suffering from MS or other neurological conditions. The methods of the invention also allow for the identification of new therapeutics for MS and other neurological conditions and also enables the personalized efficacy assessment of a potential therapy for an MS subject.Type: GrantFiled: January 29, 2016Date of Patent: December 3, 2019Assignees: The Regents of the University of California, Charite-Universitatsmedizin Berlin, Mt. Sinai HospitalInventors: Michael Demetriou, Alexander Brandt, Friedmann Paul, James Dennis
-
Publication number: 20190204574Abstract: It is provided a method for identifying optical aberrations. The method comprising the steps of providing at least one first optical beam and a second optical beam ; creating a combined beam by at least partially superimposing the first and the second optical beam; focusing the combined beam into or through a medium and detecting radiation excited in the medium by the combined beam due to nonlinear optical effects; detecting the radiation excited in the medium by the combined beam for each one of the phase positions, the spatial positions and/or the time positions of the first beam; and identifying aberrations using signals generated by a detection device for the plurality of the phase positions, the spatial positions and/or the time positions of the first beam relative to the second beam upon the detection of the radiation excited in the medium.Type: ApplicationFiled: April 12, 2017Publication date: July 4, 2019Applicant: CHARITÉ - UNIVERSITÄTSMEDIZIN BERLINInventors: Benjamin JUDKEWITZ, Ioannis PAPADOPOULOS
-
Publication number: 20190100727Abstract: According to the invention fibroblast-like cells obtained from heart muscle biopsies, which are CD90 negative, CD105 positive, CD117 negative and/or CD166 positive as well as cell preparations of such cells for therapy of heart diseases as well as a method for providing the latter are disclosed. The cells according to the invention are characterized by a good cultivability in cell culture. Furthermore a method for obtaining the cells and cell preparations according to the invention are disclosed.Type: ApplicationFiled: September 30, 2018Publication date: April 4, 2019Applicant: Charite Universitatsmedizin BerlinInventors: Marion Haag, Jochen Ringe, Michael Sittinger, Carsten Tschope
-
Publication number: 20190024157Abstract: The invention relates to a control preparation (e.g. comprising microorganism control cells embedded in a cold polymerising resin or plastic) for use in a method for detection of a target microorganism in microbiological pathology, comprising a plurality of section bodies joint by a joining polymer, wherein each section body comprises a matrix polymer (e.g. a cold polymerising resin or plastic). A first section body comprises a nucleic acid sequence specific for the target microorganism (e.g. microorganism cells used as positive control). A second section body comprises a second nucleic acid sequence, which in comparison to said first nucleic acid sequence, contains a deletion, an additional nucleoside or a different nucleoside in one, two, three or four positions of said second nucleic acid sequence and which does not hybridize to said first nucleic acid sequence under stringent conditions (e.g.Type: ApplicationFiled: January 27, 2016Publication date: January 24, 2019Applicant: Charité Universitätsmedizin BerlinInventor: Annette MOTER
-
Publication number: 20180235628Abstract: The invention relates to a device for separating tissue parts, wherein the device has two parallel clamping plates, wherein at least one part of one clamping plate can be pivoted away from the other clamping plate in order to receive a tissue part and can be pivoted back in order to fix the tissue part, wherein the device has at least two interconnected blades arranged at an angle to each other or has one curved or kinked blade, wherein the blade or blades is/are insertable and displaceable in guide rails of the clamping plates, and wherein a cutting edge of the blade or blades extends between the clamping plates.Type: ApplicationFiled: August 12, 2016Publication date: August 23, 2018Applicant: CHARITÉ - UNIVERSITÄTSMEDIZIN BERLINInventors: Panagiotis FIKATAS, Igor SAUER, Marcus BAHRA
-
Publication number: 20180230432Abstract: The present invention is related to a bone marrow-derived myeloid progenitor cell (MPC), preferably an isolated bone marrow-derived myeloid progenitor cell (MPC), wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD34, c-Kit (CD117) and CX3CR1.Type: ApplicationFiled: September 29, 2015Publication date: August 16, 2018Applicant: Charite-Universitatsmedizin BerlinInventors: Josef PRILLER, Chotima BOTTCHER
-
Patent number: 9974895Abstract: The present disclosure relates to a hemodialysis membrane for the treatment of vascular calcification in hemodialysis patients, especially in chronic hemodialysis patients. The present disclosure further relates to methods of treating vascular calcification in hemodialysis patients, wherein the hemodialysis membrane is characterized in that it comprises at least one hydrophobic polymer and at least one hydrophilic polymer and in that it has a MWRO of between 15 and 20 kD and a MWCO of between 170-320 kD or that the hemodialysis membrane comprises at least one hydrophobic polymer and at least one hydrophilic polymer and has a MWRO of between 8.5 kD and 14.0 kD and a MWCO of between 55 kD and 130 kD.Type: GrantFiled: October 10, 2014Date of Patent: May 22, 2018Assignees: GAMBRO LUNDIA AB, CHARITE UNIVERSITATSMEDIZIN BERLINInventors: Markus Storr, Bernd Krause, Ralf Schindler, Daniel Zickler, Bjoern Hegner
-
Publication number: 20170342111Abstract: The invention relates to isolated antibodies that bind to specific peptides and to their use in the diagnosis of celiac disease.Type: ApplicationFiled: November 20, 2015Publication date: November 30, 2017Applicant: CHARITE-UNIVERSITATSMEDIZIN BERLINInventor: Karl Skriner
-
Publication number: 20170275590Abstract: The invention relates to method for cultivating stem cells in vitro, comprising the following steps: providing a sample comprising stem cells and cultivating the stem cells by subjecting the sample to a treatment for a first period of time. The treatment is carried out under hypothermic conditions having a defined temperature and a defined atmosphere, wherein the temperature does not exceed 15° C. and the atmosphere has an oxygen content not exceeding 21% (v/v). Thereby, the first period of time is 4 days to 4 weeks.Type: ApplicationFiled: August 25, 2015Publication date: September 28, 2017Applicants: CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN, MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) BERLIN-BUCHInventors: Andreas MARG, Simone SPULER
-
Publication number: 20170264601Abstract: An authentication method wherein, in a training phase, a user is presented with a plurality of images called primed images and drawn randomly from a database (6) containing images. In an authentication phase, the user is presented with a plurality of degraded versions of at least a subset of the primed images and with a plurality of degraded versions of non-primed images extracted from the database. After receiving from the user respective identifications of the presented degraded primed images and non-primed images, a global score based is determined. The user is authenticated based upon the determined global score.Type: ApplicationFiled: June 17, 2015Publication date: September 14, 2017Applicants: INRIA INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET EN AUTOMATIQUE, CHARITE UNIVERSITATSMEDIZIN BERLINInventors: FATMA IMAMOGLU, MAXIMILIAN GOLLA, MARKUS DURMUTH, CLAUDE CASTELLUCCIA
-
Publication number: 20160207994Abstract: The invention provides antibody against p40, IL-12 or IL-23 for the prevention or treatment of Alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like-molecule, for the prevention or treatment of Alzheimer's disease. Similarly, siRNA, antisense or transcription factor modulators of gene expression of p19, p35, p40, IL-12R-?1, IL-12R-?2, and/or IL-23R for the prevention or treatment of Alzheimer's disease are provided.Type: ApplicationFiled: January 19, 2016Publication date: July 21, 2016Applicants: UNIVERSITAT ZURICH, CHARITE UNIVERSITATSMEDIZIN BERLINInventors: Burkhard Becher, Frank Heppner
-
Patent number: 9278145Abstract: An analysis method determines a functional parameter of an organ by measuring 13CO2 content in exhaled air of an individual to which a substrate has been administered. The reaction of the substrate in the body of the individual enriches the exhaled air with 13CO2. The maximum reaction rate of the substrate in the body is determined via a change of the measured 13CO2 content in the exhaled air using zero-order enzyme kinetics. An aqueous methacetin solution having a pH greater than 7.0 is used in the analysis method. A face mask separates the exhaled air from inhaled air. The face mask is configured such that inhaled and exhaled air flows essentially completely through the face mask. Exhalation and inhalation valves in the face mask allow a flow of inhaled and exhaled air through the face mask. A diagnostic method is used to determine the functional parameters of the organ.Type: GrantFiled: November 25, 2014Date of Patent: March 8, 2016Assignees: FREIE UNIVERSITÄT BERLIN, CHARITÉ UNIVERSITÄTSMEDIZIN BERLINInventors: Martin Stockmann, Björn Riecke
-
Patent number: 9221881Abstract: The invention relates to new peptides and to their use in the diagnosis of celiac disease.Type: GrantFiled: October 1, 2010Date of Patent: December 29, 2015Assignee: Charité-Universitätsmedizin BerlinInventor: Karl Skriner
-
Publication number: 20150329624Abstract: The present invention relates to an IgY composition characterized in that said IgY composition contains IgY antibodies, fragments, and/or Fab fragments thereof that specifically bind to a peptide with the amino acid sequence of SEQ ID NO: 1 and to the use of this IgY composition in the therapy of celiac disease, rheumatism, and/or wheat allergy.Type: ApplicationFiled: June 1, 2015Publication date: November 19, 2015Applicant: CHARITE - UNIVERSITATSMEDIZIN BERLINInventor: Karl SKRINER
-
Publication number: 20150241406Abstract: The present invention concerns means and methods for cancer diagnosis and, in particular, diagnosis of prostate cancer. Specifically, it relates to a method for diagnosing whether a subject is at risk for recunent prostate carcinoma after prostatectomy comprising determining the amount of at least one metabolite selected from Table 2 in a test sample of a subject after prostatectomy, and comparing the determined amount to a reference, whereby it is diagnosed whether the subject is at risk for recurrent prostate carcinoma after prostatectomy. Further methods provided in accordance with the present invention relate to differentiating between a malignant prostate carcinoma tissue and a non-malignant tissue and diagnosing metastasizing prostate carcinoma in a subject. Also provided are devices for carrying out the aforementioned methods.Type: ApplicationFiled: October 2, 2013Publication date: August 27, 2015Applicants: Charité Universitätsmedizin Berlin, Metanomics Health GmbHInventors: Regina Reszka, Beate Kamlage, Bianca Bethan, Klaus Jung, Michael Lein, Glen Kristiansen, Carsten Stephan
-
Publication number: 20150175970Abstract: Fibroblast-like cells obtained from heart muscle biopsies, which are CD90 negative, CD105 positive, CD117 negative and/or CD166 positive as well as cell preparations of such cells for therapy of heart diseases, as well as a method for providing the latter. The cells are characterized by a good cultivability in cell culture. Furthermore a method for obtaining the cells and cell preparations according to the invention are disclosed.Type: ApplicationFiled: March 10, 2015Publication date: June 25, 2015Applicant: Charite Universitatsmedizin BerlinInventors: Marion Haag, Jochen Ringe, Michael Sittinger, Carsten Tschope
-
Patent number: 9012401Abstract: The invention relates to novel biosynthetic growth factor mutants which exhibit improved biological activity.Type: GrantFiled: March 3, 2006Date of Patent: April 21, 2015Assignees: Biopharm Gesellschaft zur biotechnolgischen Entwicklung von Pharmaka mbH, Charite-Universitatsmedizin Berlin, Freie Universitat BerlinInventors: Stefan Mundlos, Petra Knaus, Jens Pohl, Michael Kruse, Frank Plöger